| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
In a dose-response manner, meclofenamic acid sodium hydrate (0-100 μM, 24 h) inhibits FTO demethylation [1]. Prostaglandin synthesis is inhibited by meclofenamic acid sodium hydrate, which inhibits cyclooxygenase with an IC50 of about 1 μM [2]. Meclofenamic acid sodium hydrate counteracts tissue reactions to certain prostaglandins and suppresses the release of 5-HETE and LTB4 from human neutrophils when induced by calcium ionophores [2].
|
|---|---|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HeLa Cell Tested Concentrations: 0, 12.5, 25, 50, 100 μM Incubation Duration: 24 h Experimental Results: Inhibited FTO demethylation in a dose-response manner and increased the level of m6A in cellular mRNA Targeting FTO. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Medication Use During Lactation Since there is currently no information regarding the use of meclofenamic acid during lactation, it is recommended to prioritize other medications, especially when breastfeeding newborns or premature infants. ◉ Effects on Breastfed Infants As of the revision date, no relevant published information was found. ◉ Effects on Lactation and Breast Milk As of the revision date, no relevant published information was found. |
| References |
|
| Additional Infomation |
Meclofenamic acid sodium monohydrate is the monohydrate of meclofenamic acid sodium salt. It is used to treat dysmenorrhea, osteoarthritis, and rheumatoid arthritis. It has various effects including analgesia, anticonvulsant, antitumor, antipyretic, antirheumatic, EC 1.13.11.34 (arachidonic acid 5-lipoxygenase) inhibitor, EC 1.14.99.1 (prostaglandin intraperoxidase) inhibitor, and nonsteroidal anti-inflammatory drug (NSAID). It contains anhydrous meclofenamic acid sodium. Meclofenamic acid sodium is the sodium salt form of meclofenamic acid, an anthraquinone NSAID with anti-inflammatory, antipyretic, and analgesic effects. Meclofenamic acid sodium inhibits the activity of cyclooxygenase I and II, thereby reducing the production of prostaglandins and thromboxane precursors. The reduced prostaglandin synthesis catalyzed by prostaglandin synthase is the reason why meclofenamic acid sodium exerts its therapeutic effect. Meclofenamic acid sodium can also reduce the formation of thromboxane A2 catalyzed by thromboxane synthase, thereby inhibiting platelet aggregation. It is a nonsteroidal anti-inflammatory drug with antipyretic and antiplatelet aggregation effects. It can also inhibit prostaglandin biosynthesis. See also: Meclofenamic acid (contains the active ingredient).
|
| Molecular Formula |
C14H10NO2CL2-.NA+.H2O
|
|---|---|
| Molecular Weight |
336.14578
|
| Exact Mass |
335.009
|
| CAS # |
67254-91-5
|
| Related CAS # |
Meclofenamic acid;644-62-2
|
| PubChem CID |
23663959
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.417
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
332
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl.O.[Na+]
|
| InChi Key |
QHJLLDJTVQAFAN-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C14H11Cl2NO2.Na.H2O/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;;/h2-7,17H,1H3,(H,18,19);;1H2/q;+1;/p-1
|
| Chemical Name |
sodium;2-(2,6-dichloro-3-methylanilino)benzoate;hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9749 mL | 14.8743 mL | 29.7486 mL | |
| 5 mM | 0.5950 mL | 2.9749 mL | 5.9497 mL | |
| 10 mM | 0.2975 mL | 1.4874 mL | 2.9749 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
